Rob Dillard

DocwireNews

A new study shows that upadacitinib (Rinvoq) therapy yields favorable outcomes in people hospitalized with Crohn disease (CD). The findings were presented at ACG 2024.
Upadacitinib is a JAK inhibitor approved in 2023 for treatment of CD and is effective in achieving remission, as the researchers noted. However, to date, no studies have evaluated the drug&#8217;s use in hospitalized CD patients.
In this retrospective chart review study, researchers analyzed 19 patients (all over the age of 18)  hospitalized with CD and initiated on upadacitinib.  Primary end points of interest were defined as need for surgical intervention, treatment discontinuation, and frequency of steroid-requiring flares.
The findings showed that of patients treated with upadacitinib, 21% required post-discharge surgery for disease control,  and 37% had treatment discontinued due to uncontrolled disease. Overall, most patients (85%) initiated with upadacitinib did not require steroids for persistent symptoms at the time of 90-day follow-up.
Although the study was limited by the recent of upadacitinib&#8217;s approval to treat CD, the researchers concluded that &#8220;initial results suggest favorable outcomes in hospitalized CD treated with Upadacitinib based on the primary endpoints.&#8221; Owing to the limitation, they added that more research is required &#8220;to describe the specific population of CD patients that would most benefit from its use in-hospital.&#8221;
&nbsp;
&nbsp;

Jordana Jampel

Examining the Gut-Brain Axis, Neurotrophic Dysfunction Association With Crohn Disease

Gastroenterology

Genomic Architecture of Varying Phenotypic Heart Shapes and Association With Cardiovascular Disease Risk

Preventive Cardiology

Kimmie Ng, MD, MPH

Dr. Kimmie Ng: From Concert Pianist Aspirations to Pioneering GI Cancer Research and Patient Care

GI Cancer

Latest News

Upadacitinib is Effective in Hospitalized Patients With Crohn Disease

ACG 2024

Upadacitinib (Rinvoq) therapy yields favorable outcomes in people with Crohn disease (CD).

Upadacitinib is Effective in Hospitalized Crohn Disease Patients

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe